Rob Drury-Dryden, MBA

Senior oncology commercial and brand strategy leader with 20+ years across global pharma and biopharma consulting. Built and led commercial strategy for several of the most consequential oncology brands of the past decade; Lynparza (the first PARP inhibitor) at AstraZeneca, Apalutamide at J&J Janssen, Erdafitinib launch readiness, and the EMEA prostate cancer franchise at Janssen.

Now Senior Principal at Uptake following a two-year consulting stint at Precision Biopharma Consultancy in Oxford. Brings deep European / EMEA commercial perspective, oncology-brand depth, and a "global-strategy-meets-affiliate-execution" view that is hard to find on US-centric SABs.